GlassScriptPhysician profile
Charles W Calvert
NPI 1659592012
$6,195.92
in general payments reported to CMS, 2019-2025
46 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,978 · 2020: $1,115 · 2021: $1,437 · 2022: $1,159 · 2023: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $507.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $733.02 | 2019-2023 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $515.64 | 2019-2021 | |
| Abbvie INC. | $507.57 | 2020-2023 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $445.73 | 2019-2022 | |
| Lilly USA, LLC | $407.42 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $348.06 | 2019-2022 | |
| Antares Pharma, INC. | $328.30 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $258.40 | 2019-2021 | |
| Kvk-Tech, INC. | $245.32 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $184.21 | 2019-2023 | Jornay Pm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.92 | 2019-2023 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $163.84 | 2022 | |
| Pfizer INC. | $162.17 | 2019-2023 | |
| Neos Therapeutics, LP | $132.16 | 2019-2020 | |
| Glaxosmithkline, LLC. | $124.49 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Calvert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.